Private CRO expands into Armenia

By Zachary Brennan contact

- Last updated on GMT

Related tags: Medicine, European union

Armenian flag photo courtesy of Flickr
Armenian flag photo courtesy of Flickr
US and China-based CRO FMD K&L has expanded into Armenia with a new office to support clients’ needs in the region and grow the company’s business further in Europe.  

This office will support services including study management, data management, biostatistics, programming, clinical data interchange standards consortium (CDISC)-compliant eSubmission, medical writing, such as protocol development and report writing, monitoring of European clinical sites, and safety handling.

Client Development Director Kirit Velani told that the opening of the office was all about its location as it’s “extremely desirable for any company looking to introduce themselves into the European market because Armenia can be viewed as the gateway to Europe. Now that FMD K&L Inc. has located a branch within Armenia, they have ideally situated themselves in between the US and China, two large regions within the pharmaceutical industry​.”

FMD is also already looking to expand its staff in Europe.

"We are looking to expand to a larger space in the coming months, growing our staff from 18 to 30 in 2015 and to 60 by the end of 2016​," Velani added.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more